405 related articles for article (PubMed ID: 22188921)
1. Radiotherapy and "new" drugs-new side effects?
Niyazi M; Maihoefer C; Krause M; Rödel C; Budach W; Belka C
Radiat Oncol; 2011 Dec; 6():177. PubMed ID: 22188921
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review.
Belgioia L; Desideri I; Errico A; Franzese C; Daidone A; Marino L; Fiore M; Borghetti P; Greto D; Fiorentino A;
Crit Rev Oncol Hematol; 2019 Jan; 133():163-170. PubMed ID: 30661652
[TBL] [Abstract][Full Text] [Related]
3. [Radiation therapy and targeted therapies: Risks and opportunities].
Nicolas E; Lucia F
Cancer Radiother; 2022 Oct; 26(6-7):973-978. PubMed ID: 36057520
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. [Radiotherapy and New Cancer Drugs - New Side Effects ?].
Nakamura S
Gan To Kagaku Ryoho; 2018 Mar; 45(3):424-427. PubMed ID: 29650897
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M
Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412
[TBL] [Abstract][Full Text] [Related]
7. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
9. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
10. Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.
Selzer E; Kornek G
Expert Rev Clin Pharmacol; 2013 Nov; 6(6):663-76. PubMed ID: 24164614
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in breast cancer: are heart and vessels also being targeted?
Criscitiello C; Metzger-Filho O; Saini KS; de Castro G; Diaz M; La Gerche A; de Azambuja E; Piccart-Gebhart MJ
Breast Cancer Res; 2012 Jun; 14(3):209. PubMed ID: 22713170
[TBL] [Abstract][Full Text] [Related]
12. Targeting receptor tyrosine kinases in gastric cancer.
Morishita A; Gong J; Masaki T
World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
14. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
16. Oral complications of targeted cancer therapies: a narrative literature review.
Watters AL; Epstein JB; Agulnik M
Oral Oncol; 2011 Jun; 47(6):441-8. PubMed ID: 21514211
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.
Yazici O; Sendur MA; Aksoy S
World J Gastroenterol; 2014 Jun; 20(22):6716-24. PubMed ID: 24944464
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
19. Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events?
Kurbel B; Golem AZ; Kurbel S
Future Oncol; 2015; 11(16):2307-14. PubMed ID: 26260809
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
